Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results | ANNALS OF ONCOLOGY |